z-logo
open-access-imgOpen Access
RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum]
Author(s) -
Xiaomeng Zhang,
Yongxi Song,
Na Song,
Ye Zhang,
Lingyun Zhang,
Yan Wang,
Zhenning Wang,
Xiujuan Qu,
Yunpeng Liu
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s371401
Subject(s) - cetuximab , rankl , proto oncogene tyrosine protein kinase src , cancer , cancer research , medicine , sensitivity (control systems) , receptor , colorectal cancer , activator (genetics) , electronic engineering , engineering

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here